How Viz.ai and Aidoc Built a Regulatory Clearance Moat

In AI radiology, two companies have built regulatory positions that are genuinely difficult to replicate: Viz.ai with 34+ cleared devices and Aidoc with 28+. Their clearance velocity, predicate strategy, and PCCP use create compounding regulatory advantages that go beyond any individual clearance.

This analysis is based entirely on public FDA records — 510(k) summaries, clearance dates, predicate citations, and PCCP grants — available through CDRH and tracked by AIFDA Intel.

The Clearance Velocity Advantage

Viz.ai's first FDA clearance was for stroke triage AI in 2018. By 2026, they have cleared devices across stroke, pulmonary embolism, cardiac, aortic, and multiple other indications. That's not just a commercial story — it's a regulatory infrastructure story.

Each clearance does several things:

• Establishes a cleared predicate that Viz.ai can use for future submissions
• Gives FDA reviewers experience with Viz.ai's submission format, data approach, and clinical validation methodology
• Creates cleared devices that competitors must cite (strengthening Viz.ai's market position) or avoid citing (limiting their predicate options)
• Generates real-world evidence that supports future submissions

The compound effect: by their 10th clearance, Viz.ai had established FDA familiarity that made subsequent submissions faster. By their 20th, they had a library of internal predicates that covered virtually every new indication they wanted to enter.

The Predicate Self-Citation Strategy

In CDRH records, a striking pattern emerges: Viz.ai and Aidoc frequently cite their own previously cleared devices as predicates. This is not unusual — any cleared device can be used as a predicate — but its implications are significant.

When you cite your own device as a predicate, you control the predicate. You know exactly what it claims, what performance it demonstrated, and what special controls apply. You don't need to hope that a competitor's public 510(k) summary contains enough detail to support your substantial equivalence argument.

More importantly, self-predicate citations create a tightly controlled predicate chain. Each new Viz.ai device can point back to a prior Viz.ai device, which points back to another, tracing back to early clearances under established product codes. This chain is harder for competitors to replicate without either citing Viz.ai devices (which supports Viz.ai's regulatory stature) or going back to older, less favorable predicates.

PCCP as Competitive Infrastructure

Companies with approved PCCPs can iterate their algorithms faster than competitors without them. Public clearance records show that leading AI radiology companies have prioritized PCCP approval alongside their clearances.

A PCCP that covers retraining on new site data, expanding to new imaging protocols, and performance improvements within specified bounds allows the algorithm team to operate independently of the regulatory timeline for most routine improvements. Competitors without PCCPs must submit a new 510(k) for equivalent changes — adding 6-14 months of regulatory lag to each iteration cycle.

Over 3-5 years, this regulatory agility difference becomes a significant performance gap. A company that can update its algorithm quarterly based on real-world feedback will outperform one that can update annually based on regulatory timelines.

Lessons for Emerging AI Device Companies

The strategic lessons from the leading companies' public regulatory records:

Clear early, even with a narrow indication. A limited first clearance is not a limitation — it's infrastructure. It establishes your product code, creates a self-predicate, gives FDA familiarity with your submission quality, and generates real-world evidence for future submissions.

Design your PCCP for the algorithm you'll have in three years, not the one you have today. A PCCP written around your current model architecture won't cover the improvements you'll want to make as clinical deployment generates new training data.

Build a systematic regulatory monitoring function. The companies with the strongest regulatory positions are also the ones that most systematically track what competitors are clearing, what FDA is asking for in deficiency letters, and what enforcement actions are occurring in their categories.

Think about the predicate chain you're building. Every clearance you obtain is a potential predicate for future submissions — yours and competitors'. Design your indications for use and claims with an eye toward the predicate value each clearance creates.